The notes bought back by Municipality Finance will be removed from trading at Nasdaq Helsinki
Municipality Finance Plc
Stock exchange release
29 November 2023 at 11:00 am (EET)
The notes bought back by Municipality Finance will be removed from trading at Nasdaq Helsinki
On 27 November 2023 Municipality Finance Plc announced that it has bought back its EUR 10 million notes (ISIN XS2485560481) in whole. Nasdaq Helsinki has today approved MuniFin’s application to remove the notes from trading.
MUNICIPALITY FINANCE PLC
Executive Vice President, Capital Markets and Sustainability
tel. +358 50 444 3638
MuniFin (Municipality Finance Plc) is one of Finland’s largest credit institutions. The owners of the company include Finnish municipalities, the public sector pension fund Keva and the Republic of Finland. MuniFin Group also includes the subsidiary company, Financial Advisory Services Inspira Ltd. The Group’s balance sheet totals approximately EUR 48 billion.
MuniFin builds a better and more sustainable future with its customers. Our customers include municipalities, joint municipal authorities, wellbeing services counties, joint county authorities, corporate entities under the control of the above-mentioned organisations, and affordable social housing. Lending is used for environmentally and socially responsible investment targets such as public transportation, sustainable buildings, hospitals and healthcare centres, schools and day care centres, and homes for people with special needs.
MuniFin’s customers are domestic but the company operates in a completely global business environment. The company is an active Finnish bond issuer in international capital markets and the first Finnish green and social bond issuer. The funding is exclusively guaranteed by the Municipal Guarantee Board.
Read more: www.munifin.fi
The information contained herein is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into any such country or jurisdiction or otherwise in such circumstances in which the release, publication or distribution would be unlawful. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any securities or other financial instruments in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.
This communication does not constitute an offer of securities for sale in the United States. The notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of any state of the United States and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r
Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release
Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of the delisting procedure and consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a
798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release
BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,